Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
Recruiting · NCT07401121 · Registry updated 2026-02-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 | 2026-02-10 | NCT07401121 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celosia Therapeutics Pty Ltd | 1 |
| Novotech (Australia) Pty Limited | 15 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Macquarie University Hospital | Sydney | Australia | 9 |